The Charles Bronfman Institute for Personalized Medicine

BioMe Biobank

The Charles Bronfman Institute for Personalized Medicine is revolutionizing medicine and health care based on your personal DNA and data. Our world-class faculty is leading the way in discovering genetic underpinnings of common diseases and in advancing genome-informed medicine at the Mount Sinai Health System.

In the News

Feb 01, 2021

Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans

Soluble urokinase plasminogen activator receptor (suPAR) is the circulating form of urokinase plasminogen activator receptor, a glycosyl-phosphatidylinositol–anchored membrane protein expressed in various cell types including kidney podocytes and endothelial cells.

Jan 27, 2021

Integrated Spatial Genomics Reveals Global Architecture of Single Nuclei

Identifying the relationships between chromosome structures, nuclear bodies, chromatin states and gene expression is an overarching goal of nuclear-organization studies.

Dec 04, 2020

Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months

BioMe called “heroes” for providing 360 de-identified plasma samples to Mount Sinai’s Department of Pathology, Molecular and Cell-based Medicine to help “define the normal level of Cytokines and anti COVID19 Antibodies required by the NYSDOH Wadsworth Center.”

Nov 23, 2020

Discovery of Rare Variants Associated with Blood Pressure Regulation Through Meta-analysis of 1.3 Million Individuals

Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele frequency > 0.05).

Oct 23, 2020

Autoantibodies Against Type I IFNs in Patients with Life-Threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast.

Jun 09, 2020

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Polygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy.

Twitter

Loading Tweets...

Videos

View All Videos

BioMe: Channeling the power of genomics and BIG data

PharmaCoGenomics at Mount Sinai Health System in New York City

Sharing genetic information with African American patients to prevent kidney disease -- Mt. Sinai

Mount Sinai Innovation in Devices, Diagnostics & Clinical Trials - SINAInnovations 2012 Conference

Whole Genome Sequencing and You

Introduction to the Charles Bronfman Institute for Personalized Medicine

Mount Sinai Receives TOPMed Grant For BioMe BioBank

Meet Our Team

Featured Labs

Loos Lab

Gaining insight in the biology that controls body weight

Loos Lab

Gaining insight in the biology that controls body weight

Cho Lab

Investigating genetic and immunologic factors associated with inflammatory bowel disease

Kenny Lab

Analyzing human genetic variation to address questions in biology, medicine, and anthropology

Latest Publications

Judy H. Cho, MD
The Promise of Epigenetics: Has it Delivered New Insights?

Ron Do, PhD
Rare Variant in Scavenger Receptor BI Raises HDL Cholesterol and Increases Risk of Coronary Heart Disease

Eimear Kenny, PhD
GBStools: A Statistical Method for Estimating Allelic Dropout in Reduced Representation Sequencing Data

Ruth Loos, PhD
Testing the Role of Predicted Gene Knockouts in Human Anthropometric Train Variation

Girish Nadkarni, MD, MPH
Genomics in CKD: Is This the Path Forward?

Aniwaa Owusu Obeng, PharmD
Genetic Variation among 82 Pharmacogenes: The PGRN-Seq Data From the eMERGE Network

Stuart Scott
Polygenic Overlap Between Schizophrenia Risk and Antipsychotic Response: A Genomic Medicine Approach

Inga Peter
Mutation Screening of Candidate Genes in Patients With Nonsyndromic Sagittal Craniosynostosis

View All Publications

Contact the Institute